Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Working to Meet with FDA on Possible Phase 3 COVID-19 Trial

Stockhouse Editorial April 8, 2021

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

GlobeNewswire April 8, 2021

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

GlobeNewswire April 6, 2021

Algernon Pharmaceuticals (CSE:AGN) reports on latest phase of its Ifenprodil COVID-19 trial

Trevor Abes  March 31, 2021

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

GlobeNewswire March 31, 2021

Algernon Joins the First Psychedelic Stock Index ETF on the Market

Stockhouse Editorial March 29, 2021

Algernon Pharmaceuticals (CSE:AGN) added to the Horizons Psychedelic Stock Index ETF

John Ballem  March 29, 2021

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

GlobeNewswire March 29, 2021

Algernon (CSE:AGN) submits FDA meeting request for DMT clinical research program

Trevor Abes  March 17, 2021

Algernon Requests Psychedelic Drug Clinical Research Program for Stroke from FDA

Stockhouse Editorial March 17, 2021

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

GlobeNewswire March 17, 2021

Algernon Pharmaceuticals (CSE:AGN) provides update on Phase 2b/3 COVID-19 trial of Ifenprodil

Brieanna McCutcheon  March 11, 2021

Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

GlobeNewswire March 11, 2021

Algernon Pharmaceuticals Announces Increase and Close of Private Placement

GlobeNewswire March 5, 2021

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

GlobeNewswire March 3, 2021

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire March 2, 2021

Algernon Pharmaceuticals (CSE:AGN) to conduct DMT Stroke Program study

Brieanna McCutcheon  March 1, 2021

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

GlobeNewswire March 1, 2021

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

GlobeNewswire March 1, 2021

Algernon Pharmaceuticals (CSE:AGN) CEO to speak at the Psychedelic Capital Virtual Investment Conference

John Ballem  February 25, 2021